Michael Mcmullen

Former President & Chief Executive Officer, Agilent

Search every verified Michael Mcmullen interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. During Agilent's Q3 2021 earnings call, McMullen reported double-digit growth in the biopharma sector across platforms including cell analysis, LC, and LCMS, as well as in consumables and services. He stated that the company was not seeing significant changes in its ability to conduct business between the United States and China, despite ongoing trade tensions. McMullen also noted that the company's long-term margin expansion story remained intact, driven by increased digital investments and reduced travel expenses. In a separate interview supporting the ARCS NCC organization, McMullen described Agilent as a "mission-driven company" that helps customers "improve, impact the human condition" by providing instrumentation and chemistries to advance quality of life. He said the "real hook" for supporting ARCS was the ability to "make a difference" by helping young researchers who are "driven, motivated, and passionate about the research."